Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024, reflecting a significant reduction in costs [17] - Revenues for 2025 totaled approximately $3.9 million, down from approximately $5.6 million in the previous year, primarily due to lower revenue from AgPlenus [22] - The net loss for 2025 was approximately $7.8 million compared to approximately $18.1 million in the same period last year, indicating improved financial performance [31] Business Line Data and Key Metrics Changes - R&D expenses for 2025 were approximately $8 million, a decrease of approximately $4.5 million compared to 2024, mainly due to reduced expenses in Biomica, Casterra, and AgPlenus [24] - Sales and marketing expenses for 2025 were approximately $1.5 million, down from approximately $2 million in the previous year, reflecting cost-cutting measures [25] - AgPlenus continues to apply ChemPass AI for the development of novel herbicides and fungicides, with expectations for growth through collaborations with Bayer and Corteva [14] Market Data and Key Metrics Changes - Casterra Ag ceased operations in Kenya and is focusing on the Brazilian market, leading to an impairment of approximately $2.2 million related to seed inventory [19] - The agricultural market has seen a decline in demand, affecting Casterra's operations, but there is an expectation of increased collaboration opportunities as the need for innovation grows [41] Company Strategy and Development Direction - The company has shifted its focus to two high-impact markets: human health and agriculture, utilizing the ChemPass AI platform for drug development and ag chemicals [8] - The strategic transformation includes discontinuing non-core activities and resizing the organization to enhance operational efficiency [7] - The long-term goal is to develop a proprietary product pipeline while becoming the partner of choice for small molecule discovery and optimization [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of strategic partnerships and collaborations to enhance the company's capabilities and market position [12] - The company expects to maintain sufficient cash flow for operations for at least a year and a half, even without additional financial transactions [36] - Management anticipates significant future catalysts, including technology collaborations and partnerships with larger biotech and ag chemical companies [39][41] Other Important Information - The company recognized a gain on the sale of Lavie Bio's assets, amounting to approximately $6.4 million, which contributed to the income from discontinued operations [31] - As of December 31, 2025, the company held approximately $13 million in cash equivalents and short-term bank deposits [21] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on the advancement of BMC128 and revenue sharing from the end product [34] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year, with sufficient cash for over a year and a half [36] Question: What are the expected investor catalysts over the coming 12 months? - Anticipated catalysts include technology collaborations with companies like Google, additional agreements with biotech and pharma companies, and collaborations with ag chemical companies [39][41]

Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024 [16] - Total operating expenses net for Q4 2025 were approximately $3.2 million, down from approximately $4.3 million in Q4 2024 [16] - Revenues for 2025 totaled approximately $3.9 million, a decrease from approximately $5.6 million in 2024 [21] - Net loss for 2025 was approximately $7.8 million compared to approximately $18.1 million in the previous year [30] - Operating loss for Q4 2025 was approximately $5.2 million, an increase from approximately $3.5 million in Q4 2024 [26] Business Line Data and Key Metrics Changes - Lavie Bio Ltd. completed the sale of the majority of its operations, significantly reducing its operational expenses [17] - Biomica scaled down operations and entered into a license agreement with Lishan Pharmaceuticals for its lead oncology candidate [17] - AgPlenus integrated into core operations, focusing on novel ag chemical products [18] - Casterra Ag ceased operations in Kenya and recorded an impairment of approximately $2.2 million related to its seed inventory [18][22] Market Data and Key Metrics Changes - The demand for castor seeds significantly declined, impacting Casterra's operations [18] - The agriculture industry has faced negative performance, affecting collaboration willingness, but there are signs of improvement [40] Company Strategy and Development Direction - The company has focused on two high-impact markets: human health and agriculture, utilizing ChemPass AI for drug development and ag chemicals [8] - A strategic transformation was initiated to streamline operations and enhance long-term value creation [6] - The mission is to become the partner of choice for small molecule discovery and optimization in pharma and agriculture [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of reduced expense levels and the potential for cash inflow from Lavie Bio and Biomica [35] - The company anticipates significant future collaborations with technology and pharmaceutical companies, which could serve as catalysts for growth [36][40] Other Important Information - The company held consolidated cash equivalents of approximately $13 million as of December 31, 2025 [20] - Financing income net for 2025 was approximately $0.6 million, a decrease from approximately $4 million in the previous year [26] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on advancing BMC128 and revenue sharing from the end product [33] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year [35] Question: What are the expected investor catalysts over the coming 12 months? - Three types of catalysts were identified: technology collaborations, additional pharma collaborations, and ag chemical collaborations [36][40]

Core Viewpoint - A group of 14 law firms representing nearly 20,000 plaintiffs is challenging Bayer's proposed class-action settlement regarding Roundup litigation, expressing concerns about fairness for cancer sufferers [1][2][3] Group 1: Settlement Proposal Details - Bayer announced a proposed class-action settlement of $7.25 billion on February 17, offering payments between $10,000 and $165,000 to users of glyphosate-based products who have or may develop non-Hodgkin lymphoma (NHL) [6][7] - The settlement proposal includes a provision for preliminary court approval within a 15-day period, which the opposing law firms are seeking to extend by 60 days for broader public participation and scrutiny [5] Group 2: Concerns Raised by Opposing Law Firms - The law firms argue that the settlement appears "unprecedented" and raises multiple "red flags," suggesting it heavily favors occupational users of Roundup, such as farmers, over residential users [3][8] - The proposed payment schedule indicates that an occupational claimant diagnosed before age 60 with aggressive NHL could receive an average of $165,000, while a residential user with similar traits would average only $40,000 [8] Group 3: Bayer's Legal Challenges - Since acquiring Monsanto in 2018, Bayer has faced over 100,000 lawsuits related to Roundup, resulting in billions of dollars paid in settlements and jury verdicts to individuals claiming NHL due to glyphosate exposure [7]

Core Viewpoint - Bayer AG proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer, originally made by Monsanto, which Bayer acquired in 2018 for over $60 billion [1] Group 1: Settlement Details - The proposed settlement aims to provide closure for Bayer, reducing litigation uncertainty and potential exposure from future Supreme Court rulings [2] - Monsanto will fund the settlement through capped annual payments over up to 21 years, totaling as much as $7.25 billion, and has agreed to settle additional Roundup cases under confidential terms [3] - The settlement proposal was filed in Missouri's St. Louis Circuit Court, where many lawsuits were initiated, claiming inadequate warnings about non-Hodgkin lymphoma risks associated with glyphosate [4] Group 2: Legal Context - The proposed settlement comes as the U.S. Supreme Court prepares to hear arguments regarding Bayer's assertion that EPA's approval of Roundup without a cancer warning should nullify state court claims, and the settlement will not impact this case [5] - Bayer's Monsanto unit secured a significant legal victory when a Washington state appeals court overturned a $185 million verdict against the company related to chemical contamination [6] - The Trump administration backed Bayer in its Roundup cases, urging the Supreme Court to limit state-law claims, which could provide regulatory clarity for farmers [7]

Core Viewpoint - The U.S. President's executive order utilizing the Defense Production Act highlights the necessity for U.S. farmers to have reliable access to glyphosate, as stated by Bayer [1] Group 1: Executive Order and Its Implications - The executive order aims to secure the supply of glyphosate, a critical herbicide for U.S. agriculture [1] - Bayer emphasizes the importance of glyphosate for farmers, indicating that access to this herbicide is essential for maintaining agricultural productivity [1] Group 2: Industry Impact - The move reflects broader concerns within the agricultural sector regarding the availability of essential farming inputs [1] - This action may influence market dynamics, potentially affecting glyphosate pricing and availability for farmers across the U.S. [1]

Core Points - President Trump issued an executive order to promote domestic production of phosphorus and glyphosate, citing their importance for national defense and food security [2][5] - The order mandates Agriculture Secretary Brooke Rollins to implement regulations to increase the supply of these chemicals [4] - There is currently only one domestic producer of elemental phosphorus and glyphosate-based herbicides, making the supply chain vulnerable to foreign threats [5] Company Insights - Bayer, the manufacturer of glyphosate-based herbicide Roundup, is involved in ongoing litigation regarding the chemical's alleged links to cancer, with a proposed settlement of $7.25 billion for lawsuits [3] - Monsanto, now owned by Bayer, emphasized the necessity for U.S. farmers to access domestically produced crop protection tools like glyphosate and stated compliance with the executive order [7] - The executive order reflects a shift in the stance of health officials, who previously expressed concerns about glyphosate but now recognize its importance for farmers [6]

Core Viewpoint - The US Supreme Court has agreed to hear Bayer's appeal to limit lawsuits claiming that its Roundup weedkiller causes cancer, which could potentially save the company billions in damages [1][2]. Group 1: Legal Proceedings - Bayer is appealing a Missouri Court of Appeals ruling that upheld a $1.25 million verdict awarded to a plaintiff diagnosed with non-Hodgkin's lymphoma after using Roundup [2][4]. - The company argues that federal law governing pesticides should preempt state law claims, as the Environmental Protection Agency (EPA) has not found evidence that Roundup increases cancer risk [7][14]. - Bayer is currently facing approximately 65,000 similar claims in state and federal courts related to Roundup [4][8]. Group 2: Financial Implications - Bayer shares rose nearly 5% following the announcement that the Supreme Court would hear the case [2][8]. - The company has already paid around $10 billion to settle most Roundup lawsuits pending as of 2020, but has not reached a settlement for future cases [11]. - A favorable ruling from the Supreme Court could significantly reduce the number of lawsuits Bayer faces, potentially saving the company billions in damages [1][9]. Group 3: Company Strategy - Bayer's CEO, Bill Anderson, stated that the court's decision is a crucial part of the company's strategy to manage ongoing litigation [3]. - The company has indicated that it may withdraw Roundup from the US market if litigation continues to escalate [15]. - Bayer acquired Roundup as part of its $63 billion purchase of Monsanto in 2018 and maintains that decades of studies support the safety of glyphosate, the active ingredient in Roundup [12][16].

Core Viewpoint - The U.S. Supreme Court has agreed to hear Bayer's request to significantly limit lawsuits alleging that its Roundup weedkiller causes cancer, which could potentially save the company billions of dollars in damages [1] Group 1 - Bayer is seeking to limit the legal claims against its Roundup product, which has faced numerous lawsuits related to cancer allegations [1] - The Supreme Court's decision to hear the case indicates a significant legal development that could impact Bayer's financial liabilities [1] - A favorable ruling for Bayer could lead to a reduction in the number of lawsuits and associated damages, benefiting the company's financial outlook [1]

Market Overview - The Shanghai Composite Index fell by 0.6%, the Shenzhen Component Index decreased by 0.44%, the ChiNext Index dropped by 1.02%, and the Northern Stock 50 declined by 2.31% [1] - The total market turnover was 1,895.2 billion yuan, a decrease of 350.6 billion yuan compared to the previous day [1] Sector Performance - Precious metals, energy metals, and agricultural chemicals sectors were active, while commercial aerospace and AI application sectors experienced adjustments [1] - The precious metals sector continued to strengthen, with Sichuan Gold hitting the daily limit, and Hunan Silver and Xiaocheng Technology rising nearly 6% [1] - The energy metals sector saw gains, with Huayou Cobalt and Yuanhang Precision increasing over 6% [1] - The agricultural chemicals sector performed well in the morning, with Dongfang Tower rising over 8%, and Baiao Chemical and Lianhua Technology increasing over 7% [1] Notable Declines - The commercial aerospace sector adjusted, with multiple stocks such as Zhongke Xingtou, Tianrun Technology, and Hongxiang Co. falling over 10% [1] - Stocks like Leike Defense, Changjiang Communication, and Aerospace Electronics hit the daily limit down [1] - The AI application sector also faced adjustments, with Tianlong Group, Zhidema, and Hongbo Medicine hitting the daily limit down, and stocks like Tongda Hai and Guangha Communication dropping over 10% [1]

Financial Performance - American Vanguard's adjusted EBITDA increased by over 350% to $8.2 million compared to the year-ago period[4] - Gross profit margin increased by 300 basis points compared to last year, driven by improved factory utilization[4] - The company maintains 2025 adjusted EBITDA guidance of $40 million to $44 million and anticipates revenue of $520 million - $535 million[5] - Q3 2025 adjusted EBITDA was $8.2 million compared to $1.8 million in Q3 2024[6] - Q3 2025 gross profit margin was 29% compared to 26% in Q3 2024[6] - Net debt decreased by $2 million[19, 20] Revenue Analysis - Total net sales increased by 1% to $119.313 million in Q3 2025 from $118.307 million in Q3 2024[10] - U S Crop sales increased by 22% to $43.31 million in Q3 2025 from $35.533 million in Q3 2024[10] - U S Non-Crop sales decreased by 14% to $19.233 million in Q3 2025 from $22.454 million in Q3 2024[10] - International sales decreased by 6% to $56.77 million in Q3 2025 from $60.32 million in Q3 2024[10] Strategic Initiatives and Cost Management - The company has an attractive growth pipeline that will potentially generate $100 million of net sales over the medium-term[4] - Operating expenses decreased by 14% compared to last year[17]